These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 432517

  • 1. [Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients].
    Bataille R, Donadio D, Morlock G, Rosenberg F, Blotman F, Sany J, Simon L, Izarn P, Serre H.
    Rev Rhum Mal Osteoartic; 1979 Feb; 46(2):77-83. PubMed ID: 432517
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors and therapeutic results in multiple myeloma.
    Nagai M, Kitahara T, Minato K, Takenaka T, Konda C, Seki S, Shimoyama M.
    Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
    [Abstract] [Full Text] [Related]

  • 3. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
    Franco M, Fuzibet JG, Cassuto JP, Pesce A, Ziegler G, Dujardin P.
    Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
    [Abstract] [Full Text] [Related]

  • 4. Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients.
    Cavo M, Baccarani M, Galieni P, Gobbi M, Tura S.
    Nouv Rev Fr Hematol (1978); 1986 Nov; 28(3):147-52. PubMed ID: 3748798
    [Abstract] [Full Text] [Related]

  • 5. [Results of the treatment of myeloma with a vincristine-melphalan combination].
    Roux H, d'Omezon Y, Gaborit P, Eisinger F, Serratrice G.
    Rev Rhum Mal Osteoartic; 1979 Nov; 46(7-9):443-8. PubMed ID: 315613
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Prognostic factors affecting survival in multiple myeloma].
    Tornóczky J, Tóth A, Sziládi E, Hoffmann E, Liszátz M.
    Orv Hetil; 1990 Aug 05; 131(31):1679-84. PubMed ID: 2205822
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.
    Matzner Y, Benbassat J, Polliack A.
    Isr J Med Sci; 1977 Aug 05; 13(8):797-807. PubMed ID: 408296
    [No Abstract] [Full Text] [Related]

  • 9. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G, Figueroa M G, Lois V V, Cabrera C ME, León R A, García L H, Rojas R H.
    Rev Med Chil; 2008 Jan 05; 136(1):7-12. PubMed ID: 18483648
    [Abstract] [Full Text] [Related]

  • 10. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P, Colantonio D, Collacciani A, Casale R, Natali G.
    Panminerva Med; 1991 Jan 05; 33(2):93-110. PubMed ID: 1923560
    [Abstract] [Full Text] [Related]

  • 11. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Jan 05; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 12. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
    Ben Abid H, Meddeb B, Ben Abdallah M, Bel Hadj Ali Z, Hafsia R, Ben Lakhal R, Gouider E, Aissaoui L, Landoulsi I, ben Abdeladhim A, Hafsia A.
    Tunis Med; 2000 Dec 05; 78(12):705-12. PubMed ID: 11155374
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.
    Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J, Horton C, Treleaven J.
    Bone Marrow Transplant; 2001 Jul 05; 28(1):29-37. PubMed ID: 11498741
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Multiple myeloma. Analysis of fifty cases.
    Venugopal P, Rajni A, Gopal R, Nair CN, Kurkure PA, Saikia TK, Nadkarni KS, Pai SK, Pai VR, Advani SH.
    J Assoc Physicians India; 1989 Jun 05; 37(6):367-70. PubMed ID: 2592326
    [Abstract] [Full Text] [Related]

  • 17. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE, Pruzanski W.
    Arch Intern Med; 1975 Jan 05; 135(1):172-6. PubMed ID: 803363
    [Abstract] [Full Text] [Related]

  • 18. [Survival of myeloma patients treated with dialysis].
    Martín Reyes G, Valera A, Frutos MA, Ramos B, Ordóñez V, López de Novales E.
    Nefrologia; 2003 Jan 05; 23(2):131-6. PubMed ID: 12778877
    [Abstract] [Full Text] [Related]

  • 19. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F, Minoia C, Favoino E, Prete M, Dammacco F.
    Blood Cells Mol Dis; 2009 Jan 05; 42(1):71-6. PubMed ID: 18996035
    [Abstract] [Full Text] [Related]

  • 20. Correlation of abnormal immunoglobulin with clinical features of myeloma.
    Arch Intern Med; 1975 Jan 05; 135(1):46-52. PubMed ID: 1111470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.